How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
54
SRTS Quote, Financials, Valuation and Earnings
Last price:
$5.18
Seasonality move
:
-12.98%
Day range:
$5.00 - $5.18
52-week range:
$3.03 - $9.08
Dividend yield:
0%
P/E ratio:
34.65x
P/S ratio:
2.35x
P/B ratio:
1.64x
Volume:
102.7K
Avg. volume:
99.5K
1-year change:
-26.16%
Market cap:
$83.9M
Revenue:
$41.8M
EPS (TTM):
-$0.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SRTS
Sensus Healthcare, Inc.
|
$8.3M | -$0.05 | -36.14% | -25.98% | $7.33 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 227.21% | -28.83% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SRTS
Sensus Healthcare, Inc.
|
$5.11 | $7.33 | $83.9M | 34.65x | $0.00 | 0% | 2.35x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.5600 | $12.3077 | $190.3M | -- | $0.00 | 0% | 173.58x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.11 | $14.20 | $164.9M | 31.01x | $0.00 | 0% | 1.22x |
|
VNRX
VolitionRX Ltd.
|
$0.26 | $2.20 | $31.9M | -- | $0.00 | 0% | 17.82x |
|
VTAK
Catheter Precision, Inc.
|
$2.09 | -- | $2.6M | 0.40x | $0.00 | 0% | 9.83x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.64 | $1.50 | $88.9M | 62.25x | $0.00 | 0% | 0.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SRTS
Sensus Healthcare, Inc.
|
1.03% | 1.475 | 1.03% | 4.98x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SRTS
Sensus Healthcare, Inc.
|
$2.7M | -$2.6M | -5.58% | -5.65% | -37.32% | $2.3M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Sensus Healthcare, Inc. vs. Competitors
-
Which has Higher Returns SRTS or CATX?
Perspective Therapeutics, Inc. has a net margin of -13.7% compared to Sensus Healthcare, Inc.'s net margin of -12425.36%. Sensus Healthcare, Inc.'s return on equity of -5.65% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital SRTSSensus Healthcare, Inc.39.41% -$0.06 $51.7M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About SRTS or CATX?
Sensus Healthcare, Inc. has a consensus price target of $7.33, signalling upside risk potential of 43.51%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 380.77%. Given that Perspective Therapeutics, Inc. has higher upside potential than Sensus Healthcare, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Sensus Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRTSSensus Healthcare, Inc.2 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is SRTS or CATX More Risky?
Sensus Healthcare, Inc. has a beta of 1.211, which suggesting that the stock is 21.098% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock SRTS or CATX?
Sensus Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRTS or CATX?
Sensus Healthcare, Inc. quarterly revenues are $6.9M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Sensus Healthcare, Inc.'s net income of -$943K is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Sensus Healthcare, Inc.'s price-to-earnings ratio is 34.65x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare, Inc. is 2.35x versus 173.58x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRTSSensus Healthcare, Inc.2.35x 34.65x $6.9M -$943K CATXPerspective Therapeutics, Inc.173.58x -- $209K -$26M
-
Which has Higher Returns SRTS or INFU?
InfuSystem Holdings, Inc. has a net margin of -13.7% compared to Sensus Healthcare, Inc.'s net margin of 6.19%. Sensus Healthcare, Inc.'s return on equity of -5.65% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital SRTSSensus Healthcare, Inc.39.41% -$0.06 $51.7M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About SRTS or INFU?
Sensus Healthcare, Inc. has a consensus price target of $7.33, signalling upside risk potential of 43.51%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 75.09%. Given that InfuSystem Holdings, Inc. has higher upside potential than Sensus Healthcare, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than Sensus Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRTSSensus Healthcare, Inc.2 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is SRTS or INFU More Risky?
Sensus Healthcare, Inc. has a beta of 1.211, which suggesting that the stock is 21.098% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock SRTS or INFU?
Sensus Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRTS or INFU?
Sensus Healthcare, Inc. quarterly revenues are $6.9M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Sensus Healthcare, Inc.'s net income of -$943K is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Sensus Healthcare, Inc.'s price-to-earnings ratio is 34.65x while InfuSystem Holdings, Inc.'s PE ratio is 31.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare, Inc. is 2.35x versus 1.22x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRTSSensus Healthcare, Inc.2.35x 34.65x $6.9M -$943K INFUInfuSystem Holdings, Inc.1.22x 31.01x $36.5M $2.3M
-
Which has Higher Returns SRTS or VNRX?
VolitionRX Ltd. has a net margin of -13.7% compared to Sensus Healthcare, Inc.'s net margin of -862.39%. Sensus Healthcare, Inc.'s return on equity of -5.65% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SRTSSensus Healthcare, Inc.39.41% -$0.06 $51.7M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About SRTS or VNRX?
Sensus Healthcare, Inc. has a consensus price target of $7.33, signalling upside risk potential of 43.51%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 746.15%. Given that VolitionRX Ltd. has higher upside potential than Sensus Healthcare, Inc., analysts believe VolitionRX Ltd. is more attractive than Sensus Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRTSSensus Healthcare, Inc.2 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is SRTS or VNRX More Risky?
Sensus Healthcare, Inc. has a beta of 1.211, which suggesting that the stock is 21.098% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock SRTS or VNRX?
Sensus Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRTS or VNRX?
Sensus Healthcare, Inc. quarterly revenues are $6.9M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Sensus Healthcare, Inc.'s net income of -$943K is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Sensus Healthcare, Inc.'s price-to-earnings ratio is 34.65x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare, Inc. is 2.35x versus 17.82x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRTSSensus Healthcare, Inc.2.35x 34.65x $6.9M -$943K VNRXVolitionRX Ltd.17.82x -- $627.3K -$5.4M
-
Which has Higher Returns SRTS or VTAK?
Catheter Precision, Inc. has a net margin of -13.7% compared to Sensus Healthcare, Inc.'s net margin of -1037.17%. Sensus Healthcare, Inc.'s return on equity of -5.65% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital SRTSSensus Healthcare, Inc.39.41% -$0.06 $51.7M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About SRTS or VTAK?
Sensus Healthcare, Inc. has a consensus price target of $7.33, signalling upside risk potential of 43.51%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1718.24%. Given that Catheter Precision, Inc. has higher upside potential than Sensus Healthcare, Inc., analysts believe Catheter Precision, Inc. is more attractive than Sensus Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRTSSensus Healthcare, Inc.2 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is SRTS or VTAK More Risky?
Sensus Healthcare, Inc. has a beta of 1.211, which suggesting that the stock is 21.098% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock SRTS or VTAK?
Sensus Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRTS or VTAK?
Sensus Healthcare, Inc. quarterly revenues are $6.9M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Sensus Healthcare, Inc.'s net income of -$943K is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Sensus Healthcare, Inc.'s price-to-earnings ratio is 34.65x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare, Inc. is 2.35x versus 9.83x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRTSSensus Healthcare, Inc.2.35x 34.65x $6.9M -$943K VTAKCatheter Precision, Inc.9.83x 0.40x $226K -$2.3M
-
Which has Higher Returns SRTS or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -13.7% compared to Sensus Healthcare, Inc.'s net margin of 3.93%. Sensus Healthcare, Inc.'s return on equity of -5.65% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital SRTSSensus Healthcare, Inc.39.41% -$0.06 $51.7M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About SRTS or XTNT?
Sensus Healthcare, Inc. has a consensus price target of $7.33, signalling upside risk potential of 43.51%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 136.22%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Sensus Healthcare, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Sensus Healthcare, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SRTSSensus Healthcare, Inc.2 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is SRTS or XTNT More Risky?
Sensus Healthcare, Inc. has a beta of 1.211, which suggesting that the stock is 21.098% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock SRTS or XTNT?
Sensus Healthcare, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensus Healthcare, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SRTS or XTNT?
Sensus Healthcare, Inc. quarterly revenues are $6.9M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Sensus Healthcare, Inc.'s net income of -$943K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Sensus Healthcare, Inc.'s price-to-earnings ratio is 34.65x while Xtant Medical Holdings, Inc.'s PE ratio is 62.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensus Healthcare, Inc. is 2.35x versus 0.69x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SRTSSensus Healthcare, Inc.2.35x 34.65x $6.9M -$943K XTNTXtant Medical Holdings, Inc.0.69x 62.25x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
